MedTrace Logo

Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer

NCT02407912 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-11-20

No results posted yet for this study

Summary

To assess the effect and toxicity of intrapleural administration of hypertonic cisplatin for malignant pleural effusion in patients with non-small-cell lung cancer.

Conditions

  • Pleural Effusion, Malignant

Interventions

DRUG

cisplatin

ciplatin in distilled water is injected into the chest for 48 h.

Sponsors & Collaborators

  • Shantou University Medical College

    lead OTHER

Principal Investigators

  • Hongbiao Wang, Master · Affiliated Cancer Hospital of Shantou University Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2018-03-31
Completion
2020-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02407912 on ClinicalTrials.gov